The popularity of Sildenafil initially drove a period of growth for pharma, but recent changes present a uncertain outlook for shareholders. Generic versions are reducing profits, and ongoing litigation add further https://haseebbtpb839409.spintheblog.com/41511234/sildenafil-and-pharma-a-risky-bet